Page last updated: 2024-08-24

irinotecan and Retroperitoneal Neoplasms

irinotecan has been researched along with Retroperitoneal Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Abad, DG; Bockorny, B; Bohana-Kashtan, O; Borad, MJ; Borazanci, E; Chaney, M; Feliu, J; Geva, R; Golan, T; Hidalgo, M; Kadosh, S; Lustig, TM; Macarulla, T; Muñoz, A; Park, JO; Pedersen, KS; Peled, A; Ponz-Sarvise, M; Ramirez, RA; Semenisty, V; Shaw, SM; Sorani, E; Stemmer, SM; Vainstein Haras, A; Von Hoff, DD; Wolpin, BM1
Arndt, CA; Casey, DL; Chi, YY; Donaldson, SS; Gupta, AA; Hawkins, DS; Lautz, TB; Rodeberg, DA; Routh, JC; Tian, J; Wolden, SL; Yock, TI1
Badreldin, W; Berney, D; Chowdhury, S; Frampton, AE; Harding, V; Harland, SJ; Krell, J; Mazhar, D; Shamash, J; Stebbing, J; Wilson, P1
Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D1
Inagaki, J; Inoue, M; Kawa, K; Sakata, N; Yagi, K; Yasui, M1

Trials

1 trial(s) available for irinotecan and Retroperitoneal Neoplasms

ArticleYear
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
    Nature medicine, 2020, Volume: 26, Issue:6

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Pancreatic Neoplasms; Peptides; Peritoneal Neoplasms; Receptors, CXCR4; Retroperitoneal Neoplasms; Survival Rate; T-Lymphocytes, Regulatory; Treatment Outcome

2020

Other Studies

4 other study(ies) available for irinotecan and Retroperitoneal Neoplasms

ArticleYear
Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
    Cancer, 2019, 09-15, Volume: 125, Issue:18

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Extremities; Female; Head and Neck Neoplasms; Humans; Infant; Infant, Newborn; Irinotecan; Male; Radiotherapy; Randomized Controlled Trials as Topic; Retroperitoneal Neoplasms; Rhabdomyosarcoma; Risk; Treatment Failure; Urinary Bladder Neoplasms; Vincristine; Young Adult

2019
The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
    BJU international, 2016, Volume: 117, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Irinotecan; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Seminoma; Testicular Neoplasms; Treatment Outcome; Young Adult

2016
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
    Nature clinical practice. Urology, 2008, Volume: 5, Issue:7

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms

2008
Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:11

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Retroperitoneal Neoplasms; Topoisomerase I Inhibitors

2005